...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
【24h】

Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial

机译：他莫昔芬依西美坦辅助跨国公司（TEAM）试验中，局部治疗对绝经后乳腺癌女性局部复发的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and purpose The TEAM trial investigated the efficacy and safety of adjuvant endocrine therapy consisting of either exemestane or the sequence of tamoxifen followed by exemestane in postmenopausal hormone-sensitive breast cancer. The present analyses explored the association between locoregional therapy and recurrence (LRR) in this population. Material and methods Between 2001 and 2006, 9779 patients were randomized. Local treatment was breast conserving surgery plus radiotherapy (BCS + RT), mastectomy without radiotherapy (MST-only), or mastectomy plus radiotherapy (MST + RT). Patients with unknown data on surgery, radiotherapy, tumor or nodal stage (n = 199), and patients treated by lumpectomy without radiotherapy (n = 349) were excluded. Results After a median follow-up of 5.2 years, 270 LRRs occurred (2.9%) among 9231 patients. The 5-years actuarial incidence of LRR was 4.2% (95% CI 3.3-4.9%) for MST-only, 3.4% (95% CI 2.4-4.2%) for MST + RT and 1.9% (95% CI 1.5-2.3%) for BCS + RT. After adjustment for prognostic factors, the hazard ratio (HR, reference BCS + RT) for LRR remained significantly higher for MST-only (HR 1.53; 95% CI 1.10-2.11), not for MST + RT (HR 0.78; 95% CI 0.50-1.22). Conclusion This explorative analysis showed a higher LRR risk after MST-only than after BCS + RT, even after adjustment for prognostic factors. As this effect was not seen for MST + RT versus BCS + RT, it might be explained by the beneficial effects of radiation treatment.
机译：背景与目的TEAM试验研究了在绝经后激素敏感型乳腺癌中由依西美坦或他莫昔芬加依西美坦组成的辅助内分泌治疗的有效性和安全性。目前的分析探讨了局部治疗与该人群复发（LRR）之间的关联。材料和方法2001年至2006年之间，对9779例患者进行了随机分组。局部治疗是保留乳房的手术加放疗（BCS + RT），不进行放疗的乳房切除术（仅MST）或行乳房切除术加放疗（MST + RT）。排除了手术，放疗，肿瘤或淋巴结分期未知数据的患者（n = 199），以及未经放疗的经肿块切除术治疗的患者（n = 349）。结果中位随访5.2年后，在9231名患者中发生了270例LRR，占发生率的2.9％。仅MST的5年LRR精算发生率为4.2％（95％CI 3.3-4.9％），MST + RT为3.4％（95％CI 2.4-4.2％）和1.9％（95％CI 1.5-2.3） ％）适用于BCS + RT。调整预后因素后，仅MST（HR 1.53; 95％CI 1.10-2.11）的LRR的危险比（HR，参考BCS + RT）仍显着较高，而不是MST + RT（HR 0.78; 95％CI） 0.50-1.22）。结论这项探索性分析显示，即使在调整预后因素后，仅MST治疗后的LRR风险也比BCS + RT治疗后更高。由于MST + RT与BCS + RT相对没有看到这种效果，因此可以用放射治疗的有益效果来解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号